REC-2282 clinical trials
Also written AR-42 and HDAC-42.
How each study uses REC-2282 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 5
Ohio State University Comprehensive Cancer Center (1) · Amir Mortazavi (1) · Alison Walker (1) · Massachusetts Eye and Ear Infirmary (1) · Recursion Pharmaceuticals Inc. (1) · Virginia Commonwealth University (1)
Studies
Open first, then newest update. How each study uses REC-2282 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and MeningiomaTerminatedEarly Phase 1Massachusetts Eye and Ear InfirmaryNCT02282917Written as AR-42
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasTerminatedPhase 2/3Recursion Pharmaceuticals Inc.NCT05130866Written as REC-2282
- HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple MyelomaCompletedPhase 1Ohio State University Comprehensive Cancer CenterNCT02569320Written as HDAC Inhibitor AR-42
- Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney CancerTerminatedPhase 1Virginia Commonwealth UniversityNCT02795819Written as AR-42
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedPhase 1Amir MortazaviNCT01129193Written as AR-42
- AR-42 and Decitabine in Treating Patients With Acute Myeloid LeukemiaCompletedPhase 1Alison WalkerNCT01798901Written as HDAC inhibitor AR-42
Codes
What other systems call REC-2282 · ClinicalTrials.gg INT016394
- NCI Thesaurus C116850HDAC Inhibitor REC-2282One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C116850 | HDAC Inhibitor REC-2282 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.